Combined modality therapy of esthesioneuroblastoma.
OBJECTIVE
Esthesioneuroblastoma (ENB) is a rare tumor of the olfactory epithelium. The objective of this study was to evaluate treatment modalities including surgery, IMRT, and chemotherapy and patient outcomes.


METHODS
A retrospective analysis was performed on a total of 21 patients. Therapy included craniofacial resection (CFR), radiotherapy, chemotherapy, or a combination of these methods.


RESULTS
The median follow-up period was 47 months. Surgery was performed in 90.4% of cases; radiotherapy was performed adjuvantly in 15 (72.7%) patients. Surgery, radiotherapy, and chemotherapy were administered to 7 (33.3%) patients. Eight (38.3%) patients had local recurrence. The 5-year crude overall survival was 71.4% and actuarial 5-year overall survival was 58% with confidence interval (CI, 25 and 81, respectively). The 5-year crude disease-free survival rate was 59% and the 5-year actuarial disease-free survival rate was 62% (CI, 28 and 83, respectively).


CONCLUSIONS
Multidisciplinary therapy of ENB should be considered, especially for Kadish C and high-grade lesions. Craniofacial resection (CFR), Intensity modulated radiation therapy (IMRT), and chemotherapy should be investigated in a multi-institution trial of ENB.
McLean
J Nicolas
JN
Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA.
Nunley
Sunjay R
SR
Klass
Carmen
C
Moore
Charles
C
Müller
Susan
S
Johnstone
Peter A S
PA
D014408:Biomarkers, Tumor / Q000032:analysis; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D018304:Esthesioneuroblastoma, Olfactory / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D009296:Nasal Cavity; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D009831:Olfactory Mucosa / Q000473:pathology; D012189:Retrospective Studies
D014408:Biomarkers, Tumor